Sandoz announced today that Sandoz Japan has received marketing authorization approval for its biosimilar filgrastim (Kyowa Hakko Kirin's GRAN®). The product, which will be marketed as Filgrastim BS ...

GRANIX (tbo-filgrastim) Injection Teva announced that the FDA has approved Tbo-filgrastim (XM02 filgrastim injection solution), the first granulocyte colony-stimulating factor (G-CSF) to be approved ...

First New Treatment for Neutropenia Approved in the United States in 10 YearsMarks First Supportive Care Therapy for Cancer Patients from Teva Oncology JERUSALEM, Aug 30, 2012 -- Teva Pharmaceutical ...

Gary Lyman, MD, MPH, an oncologist and hematologist, compares the uptake of filgrastim biosimlars with pegfilgrastim biosimilars. Gary Lyman, MD, MPH, is an oncologist, hematologist, and public health ...

The use of filgrastim vs pegfilgrastim in the auto-SCT population has been studied after high-dose melphalan in multiple myeloma patients. There were no differences in duration of grade 4 neutropenia ...

New York, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Filgrastim Market By Drug Type, By Indication, By Distribution Channel, By Regional Outlook, ...

New York, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Filgrastim Market By Drug Type, By Indication, By Distribution Channel, By Regional Outlook, ...

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has granted approval for tbo-filgrastim (XM02 filgrastim), ...

Review the side-effects of Filgrastim as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

DUBLIN, Jan. 18, 2022 /PRNewswire/ -- The 'Global Filgrastim market By Drug Type, By Indication, By Distribution Channel, By Regional Outlook, industry Analysis Report and Forecast, 2021 - 2027' ...